Please login to the form below

Not currently logged in
Email:
Password:

Paul Blake joins Oxford BioMedica

He will lead the development of pipeline of gene and cell therapies
paul blake oxford biomedica

Oxford BioMedica has named Dr Paul Blake as chief development officer.

Dr Blake, who is already a board member at the UK-based gene therapy specialist, will assume his new role on September 1. He will head the clinical development of the company's pipeline of gene and cell therapies.

Prior to taking the position at Oxford BioMedicia Dr Blake was senior VP and chief medical officer of Canada-based biopharma AEterna Zentaris- a position he held from 2006 to 2014.

His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.

John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”

27th August 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics